Amgen (AMGN) said Saturday that Repatha in combination with cholesterol-lowering treatments showed "statistically significant and clinically meaningful reductions" in major adverse cardiovascular events in high-risk adults without a prior heart attack or stroke in a phase 3 clinical trial.

The study of more than 12,000 patients with atherosclerosis or diabetes showed that the Repatha addition reduced the risk of a composite of coronary heart disease death, heart attack or ischemic stroke by 25% and the risk of heart attack by 36%.

The Repatha addition also "significantly" reduced the risk of most secondary endpoints, the company said.

Results also showed a reduction in the risk of cardiovascular events in nearly 60% of patients in the trial with diabetes.